Defense of Elodie David’s thesis (ChemBio Group)

Friday 24th November 2023
at 2:00 pm

Pierre et Marie Curie campus
Esclangon building
Durand amphitheater

Elodie David, a PhD student in the ChemBio group, will present her work on :

« Rational design, synthesis and pharmacological evaluation of Kallikrein 8
(neuropsin) inhibitors: therapeutic application in Alzheimer’s
disease and associated dementias»

Alzheimer’s disease is a progressive neurodegenerative disease. However, to date, there is no treatment to cure this disease. A new hypothesis is that kallikrein 8 (KLK8), a major serine protease of the central nervous system, is involved in the development of various pathophysiological pathways associated with Alzheimer’s disease. No potential therapeutic inhibitor targeting KLK8 exists to date. After a screening of molecules, we discovered two chemical series of molecules inhibiting KLK8, a first series presenting the 1,2,4-triazole moiety and the second series presenting the N,N,N-triacylamine moiety. The goal of my thesis is therefore to design and synthesize inhibitors with different pharmacomodulations on the two chemical series in order to improve inhibition and to study the structure-activity relationship of inhibitors on KLK8.

Find out more about the CHEMBIO group